首页 / 院系成果 / 成果详情页

Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma  期刊论文  

  • 编号:
    26dc45af-7136-48f5-8d75-372cdfbcc36d
  • 作者:
    Liu, Kun[1,5] Zhang, Yuening[1] Zhang, Chengdong[1,6] Zhang, Qinle[2] Li, Jiatong[1] Xiao, Feifan[1] Li, Yingfang[3] Zhang, Ruoheng[1] Dou, Dongwei[1] Liang, Jiezhen[4] Qin, Jian[7] Lin, Zhidi[1] Zhao, Dong[1] Jiang, Min[1] Liang, Zhenxin[1] Su, Jie[8] Gupta, Vanaparthy Pranay[1] He, Min[7] Yang, Xiaoli[1]
  • 语种:
    English
  • 期刊:
    ONCOTARGET ISSN:1949-2553 2016 年 7 卷 35 期 (56798 - 56810) ; AUG 30
  • 收录:
  • 关键词:
  • 摘要:

    The abnormality of DNA methylation is one of the major epigenetic alterations in the human hepatocellular carcinoma (HCC). We have assessed the global genomic DNA methylation profiles in human HCC patients by using the Infinium Human Methylation27 BeadChip. A CpG loci of S100A8 was found to be significantly hypomethylated in HCC. Pooled meta-analysis of five validation public datasets demonstrated its methylation level was significantly lower for HCC compared to paired adjacent normal tissues. Quantitative pyrosequencing analysis also showed that the S100A8 methylation level was decreased in cancer tissues (31.90%+/- 13.31%) than that in the paired adjacent normal tissues (65.33%+/- 3.64%, p<0.01). The area under the ROC curve (AUC) value was 0.950 (p<0.01). Kaplan-Meier survival curves revealed that hypomethylation of S100A8 was associated with shortened overall survival (OS) and progression-free survival (PFS) (log rank p<0.05). Multivariate Cox proportional hazards model also indicated significantly shorter OS (HR, 1.709; 95 % CI, 1.127-2.591) and PFS (HR, 1.767; 95 % CI, 1.168-2.974) were observed in the low-methylation-level group compared to the high-methylation-level group. Furthermore, S100A8 overexpression in Huh7 and MHCC-97H hepatoma cell lines led to increased cell proliferation, migration, invasion, and tumor growth. These findings suggested S100A8 methylation to be served as potential diagnosis and prognosis marker for HCC. S100A8 also may play as a tumor promoter in HCC.

  • 推荐引用方式
    GB/T 7714:
    Liu Kun,Zhang Yuening,Zhang Chengdong, et al. Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma [J].ONCOTARGET,2016,7(35):56798-56810.
  • APA:
    Liu Kun,Zhang Yuening,Zhang Chengdong,Zhang Qinle,&Yang Xiaoli.(2016).Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma .ONCOTARGET,7(35):56798-56810.
  • MLA:
    Liu Kun, et al. "Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma" .ONCOTARGET 7,35(2016):56798-56810.
浏览次数:1 下载次数:0
浏览次数:1
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部